Castle Biosciences, Inc.
CSTL
$25.62
-$0.29-1.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4.78% | -3.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.78% | -3.65% | |||
| Cost of Revenue | -2.08% | 6.12% | |||
| Gross Profit | 6.77% | -6.16% | |||
| SG&A Expenses | 1.47% | -3.72% | |||
| Depreciation & Amortization | 0.00% | 16.06% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.10% | -0.65% | |||
| Operating Income | 43.75% | -60.06% | |||
| Income Before Tax | -603.11% | -169.93% | |||
| Income Tax Expenses | -432.17% | 102.46% | |||
| Earnings from Continuing Operations | -365.47% | -111.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -365.47% | -111.08% | |||
| EBIT | 43.75% | -60.06% | |||
| EBITDA | 95.74% | -40.11% | |||
| EPS Basic | -362.21% | -111.00% | |||
| Normalized Basic EPS | 78.45% | -195.82% | |||
| EPS Diluted | -297.50% | -113.33% | |||
| Normalized Diluted EPS | 78.45% | -202.14% | |||
| Average Basic Shares Outstanding | 0.89% | 0.55% | |||
| Average Diluted Shares Outstanding | 0.89% | -1.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||